TY - JOUR
T1 - Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas
T2 - a review of 124 patients
AU - El-Galaly, Tarec Christoffer
AU - Pedersen, Martin Bjerregård
AU - Hutchings, Martin
AU - Mylam, Karen Juul
AU - Madsen, Jakob
AU - Gang, Anne Ortved
AU - Bøgsted, Martin
AU - de Nully Brown, Peter
AU - Loft, Annika
AU - Nielsen, Anne Lerberg
AU - Hendel, Helle Westergreen
AU - Iyer, Victor
AU - Gormsen, Lars Christian
N1 - © 2015 Wiley Periodicals, Inc.
PY - 2015
Y1 - 2015
N2 - According to the updated guidelines for imaging in lymphoma, 18F-FDG positron emission tomography/computed tomography (PET/CT) is recommended for staging and evaluation of treatment response in FDG-avid lymphomas.PURPOSE: The purpose of the study was to evaluate the utility of PET/CT in nodal peripheral T-cell lymphomas (PTCL).FINDINGS: Patients with newly diagnosed nodal PTCL (peripheral T-cell lymphoma NOS, anaplastic large-cell lymphoma, or angioimmunoblastic T-cell lymphoma) seen at five Danish hematology centers during the period 2006-2012 were included, if they had been pre-therapeutically staged with PET/CT. Medical records were reviewed for baseline clinical and follow-up information. Staging, interim (I-PET), and end-of-treatment PET/CT (E-PET) studies were centrally reviewed, and reported using the Deauville 5-point score (DS). A total of 124 patients fulfilled the inclusion criteria. The median age was 58 years, and 88% received CHOP/CHOP-like therapy. 5-years PFS and OS of the study population was 36.8% (95%CI 27.3-46.4) and 49.7% (95%CI 38.9-59.6), respectively. The presence of PET/CT-ascertained lung and/or liver involvement was associated with a worse outcome. The sensitivity of PET/CT for detecting biopsy-defined bone marrow involvement was only 18% (95%CI 4-43). An interim DS >3 was not prognostic for worse OS and PFS among CHOP/CHOP-like treated patients in uni- or multivariate analyses. A DS >3 after treatment predicted a worse prognosis.CONCLUSION: In conclusion, I-PET was not predictive of outcome in CHOP/CHOP-like treated PTCL patients when using the DS. Prospective studies are needed to determine the optimal use of PET/CT in PTCL including the role of quantitative PET/CT analysis. This article is protected by copyright. All rights reserved.
AB - According to the updated guidelines for imaging in lymphoma, 18F-FDG positron emission tomography/computed tomography (PET/CT) is recommended for staging and evaluation of treatment response in FDG-avid lymphomas.PURPOSE: The purpose of the study was to evaluate the utility of PET/CT in nodal peripheral T-cell lymphomas (PTCL).FINDINGS: Patients with newly diagnosed nodal PTCL (peripheral T-cell lymphoma NOS, anaplastic large-cell lymphoma, or angioimmunoblastic T-cell lymphoma) seen at five Danish hematology centers during the period 2006-2012 were included, if they had been pre-therapeutically staged with PET/CT. Medical records were reviewed for baseline clinical and follow-up information. Staging, interim (I-PET), and end-of-treatment PET/CT (E-PET) studies were centrally reviewed, and reported using the Deauville 5-point score (DS). A total of 124 patients fulfilled the inclusion criteria. The median age was 58 years, and 88% received CHOP/CHOP-like therapy. 5-years PFS and OS of the study population was 36.8% (95%CI 27.3-46.4) and 49.7% (95%CI 38.9-59.6), respectively. The presence of PET/CT-ascertained lung and/or liver involvement was associated with a worse outcome. The sensitivity of PET/CT for detecting biopsy-defined bone marrow involvement was only 18% (95%CI 4-43). An interim DS >3 was not prognostic for worse OS and PFS among CHOP/CHOP-like treated patients in uni- or multivariate analyses. A DS >3 after treatment predicted a worse prognosis.CONCLUSION: In conclusion, I-PET was not predictive of outcome in CHOP/CHOP-like treated PTCL patients when using the DS. Prospective studies are needed to determine the optimal use of PET/CT in PTCL including the role of quantitative PET/CT analysis. This article is protected by copyright. All rights reserved.
U2 - 10.1002/ajh.24128
DO - 10.1002/ajh.24128
M3 - Journal article
C2 - 26201505
SN - 0361-8609
VL - 90
SP - 975
EP - 980
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 11
ER -